<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen Y</submitter><funding>the National Key R&amp;amp;D Program of China</funding><funding>the China Postdoctoral Science Foundation</funding><funding>the National Key R&amp;D Program of China</funding><funding>the Natural Sciences Foundation of China</funding><pagination>8127-8155</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8593173</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>78(24)</volume><pubmed_abstract>Articular cartilage damage caused by sports injury or osteoarthritis (OA) has gained increased attention as a worldwide health burden. Pharmaceutical treatments are considered cost-effective means of promoting cartilage regeneration, but are limited by their inability to generate sufficient functional chondrocytes and modify disease progression. Small molecular chemical compounds are an abundant source of new pharmaceutical therapeutics for cartilage regeneration, as they have advantages in design, fabrication, and application, and, when used in combination, act as powerful tools for manipulating cellular fate. In this review, we present current achievements in the development of small molecular drugs for cartilage regeneration, particularly in the fields of chondrocyte generation and reve</pubmed_abstract><journal>Cellular and molecular life sciences : CMLS</journal><pubmed_title>Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs.</pubmed_title><pmcid>PMC8593173</pmcid><funding_grant_id>2017YFA0104900</funding_grant_id><funding_grant_id>2020M681892</funding_grant_id><funding_grant_id>81630065</funding_grant_id><funding_grant_id>82002319</funding_grant_id><pubmed_authors>Ouyang H</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Tian T</pubmed_authors><pubmed_authors>Sun H</pubmed_authors><pubmed_authors>Yao X</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Xu W</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs.</name><description>Articular cartilage damage caused by sports injury or osteoarthritis (OA) has gained increased attention as a worldwide health burden. Pharmaceutical treatments are considered cost-effective means of promoting cartilage regeneration, but are limited by their inability to generate sufficient functional chondrocytes and modify disease progression. Small molecular chemical compounds are an abundant source of new pharmaceutical therapeutics for cartilage regeneration, as they have advantages in design, fabrication, and application, and, when used in combination, act as powerful tools for manipulating cellular fate. In this review, we present current achievements in the development of small molecular drugs for cartilage regeneration, particularly in the fields of chondrocyte generation and reve</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2025-05-29T19:22:18.125Z</modification><creation>2022-02-11T12:58:49.192Z</creation></dates><accession>S-EPMC8593173</accession><cross_references><pubmed>34783870</pubmed><doi>10.1007/s00018-021-03983-8</doi></cross_references></HashMap>